$AB

AB Maintained by Evercore ISI Group -- Price Target Lowered to $

Evercore ISI Group maintained an 'Outperform' rating for AllianceBernstein Holding (AB) but lowered its price target from $42.00 to $39.00. AB has a P/E ratio of 10.34x and a GF Score™ of 35/100, indicating mixed performance. Insiders sold $185,850 worth of shares in the last three months.

Original reporting
Published Oct 9, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 11, 2026, 4:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AB
Neutral
medium confidence
Mentioned
$AB
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABNeutralMed
01

Why it matters

The price‑target cut reflects a cautious outlook but does not change the Outperform rating, suggesting limited immediate impact.

02

Market read

A modest analyst target reduction may cause short‑term price pressure but is unlikely to drive broader market moves.

03

What to watch

Potential upside if the firm improves profitability or secures new mandates.

Relevance 5/10Novelty 5/10Timing: today

Background

AllianceBernstein Holding AB is a $3.26 bn asset‑management firm with a P/E of 10.34x, considered undervalued by the analyst.

Company-level read

Ticker impact

$ABNeutralMedium confidence
Context

Evercore ISI Group lowered its price target for AllianceBernstein Holding AB from $42.00 to $39.00 while maintaining an Outperform rating.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst downgrade of price target without rating change typically leads to short-term sell pressure.

Market effects

May prompt re‑evaluation of other mid‑cap asset managers.

Limited to US equity markets.

Low, confined to the asset‑management sector.

Counterpoint

Some investors may view the unchanged Outperform rating as a buying opportunity despite the lower target.

Key entities

  • Evercore ISI Group

    Equity research firm providing the rating and target update.

  • AllianceBernstein Holding AB

    Asset‑management firm whose stock is being evaluated.

Related articles

$ABLow

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Ioanis Jorgali, Investors

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Regulation FD Disclosure. Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com AB Announces September 30, 2026 Assets Under Management Nashville, TN, October 12, 2026 - AllianceBernstein L.P. (“AB”) and Allian

$ABLow

AB Announces September 30, 2026 Assets Under Management

AllianceBernstein (NYSE: AB) reported a 2% decrease in assets under management to $900 billion in September 2026, driven by market depreciation and net outflows. Institutional channels saw inflows, offset by outflows in Retail and Private Wealth. Quarterly net inflows totaled $6.0 billion. The company issued forward-looking statements with typical cautionary language.

$ABMed

People moves: AllianceBernstein names Onur Erzan as next CEO

AllianceBernstein (AB) named Onur Erzan as its next CEO, effective April 1, 2027. Erzan, currently president, succeeds Seth Bernstein, who retires but remains on AB's board. AB's assets under management are $919 billion, with $169 billion in private wealth. Erzan joined AB in 2021 from McKinsey and has led key initiatives. AB is a subsidiary of Equitable Holdings.

$ABMedAI 8/10

AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939

AB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.

$ABMed

AllianceBernstein Holding L.P. Q2 2026 Earnings Call Summary

Strategic Execution and Platform Scaling Achieved record AUM of $905 billion, driven by a return to positive organic growth and the strongest gross sales quarter in five years. Reached the $90 billion to $100 billion private markets AUM target more than a year ahead of schedule, validating a multi-year investment strategy in corporate lending and real estate debt.

$ABMed

AllianceBernstein Holding LP (AB) Q2 2026 Earnings Call Highlights: Record AUM

AllianceBernstein (AB) discussed Q2 2026 earnings call topics, including expectations for the Equitable Corebridge merger to add about $100B of AUM over a couple of years, with combined general account assets around $350B and separate around $200B. Management cited resilient private wealth adviser productivity, reduced expense guidance by $5-10M, and demand shifts in U.S. taxable fixed income.